At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Temozolomide + Olaparibdrug
Likely dose
Temozolomide + Olaparib 75 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Temozolomide and Olaparib for O6-Methylguanine DNA Methyltransferase Promoter Hypermethylated Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating Temozolomide + Olaparib for Colorectal Cancer. Completed, enrolled 11 participants across 1 site.
Detailed Summary
This is a Phase II, non-randomized, open-label study to evaluate temozolomide in combination with olaparib in patients with MGMT promoter hypermethylated advanced colorectal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartJun 2020
Primary CompletionJan 2022
Study CompletionJun 2023
TodayJul 2026
First PostedNov 18, 2019
Enrollment StartJun 17, 2020
Primary CompletionJan 6, 2022
Study CompletionJun 12, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.6 years ago
Interventions
Temozolomide + Olaparibdrug
Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.